A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia

British Journal of Haematology

Volumn 162, Issue 4, 2013, Pages 498-508

  Andersen, Christen L ^a,b   Mcmullin, Mary F ^c   Ejerblad, Elisabeth ^d   Zweegman, Sonja ^e   Harrison, Claire ^f   Fernandes, Savio ^g   Bareford, David ^g   Knapper, Steven ^h   Samuelsson, Jan ⁱ   Löfvenberg, Eva ^j   Linder, Olle ^k   Andreasson, Bjørn ^l   Ahlstrand, Erik ^k   Jensen, Morten K ^m   Bjerrum, Ole W ^b   Vestergaard, Hanne ⁿ   Larsen, Herdis ^o   Klausen, Tobias W ^m   Mourits Andersen, Torben ^p   Hasselbalch, Hans C ^a  

^a ROSKILDE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^g RUSSELLS HALL HOSPITAL   (United Kingdom)

^h CARDIFF UNIVERSITY   (United Kingdom)

ⁱ STOCKHOLM SÖDER HOSPITAL   (Sweden)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^l UDDEVALLA HOSPITAL   (Sweden)

^m GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

ⁿ ODENSE UNIVERSITY HOSPITAL   (Denmark)

^o VIBORG HOSPITAL   (Denmark)

^p University of Esbjerg   (Denmark)

more..

Author keywords

Essential thrombocythaemia; Histone deacetylase inhibition; Phase II study; Polycythaemia vera; Vorinostat

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; HYDROXYUREA; JANUS KINASE 2; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANOREXIA; ARTICLE; BLEEDING; CHILL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAIR LOSS; HEART PALPITATION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; JAK2 GENE; KIDNEY DYSFUNCTION; LEG ULCER; LEUKOCYTOSIS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUROPATHY; OPEN STUDY; PAIN; PHASE 2 CLINICAL TRIAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SPLENOMEGALY; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOCYTOSIS; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ESSENTIAL THROMBOCYTHAEMIA; HISTONE DEACETYLASE INHIBITION; PHASE II STUDY; POLYCYTHAEMIA VERA; VORINOSTAT;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FATIGUE; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION, MISSENSE; PATIENT DROPOUTS; POLYCYTHEMIA VERA; THROMBOCYTHEMIA, ESSENTIAL; TREATMENT OUTCOME;

EID: 84880658117     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12416     Document Type: Article

References (30)

1. Akada, H., Akada, S., Gajra, A., Bair, A., Graziano, S., Hutchison, R.E. & Mohi, G. (2012) Efficacy of vorinostat in a murine model of polycythemia vera. Blood, 119, 3779-3789.
2. Andersen, C.L., McMullin, M.F., Emanuel, R., Deuck, A.C., Bareford, D., Harrison, C.N., Hasselbalch, H.C., Knapper, S., Geyer, H.L. & Mesa, R.A. (2012) Symptom Burden Among PV and ET Patients Receiving A Novel Histone Deacetylase Inhibitor: Findings From a Open-Label Phase II Study. Blood (ASH Annual Meeting Abstracts), 120, 1736.
3. Atadja, P., Gao, L., Kwon, P., Trogani, N., Walker, H., Hsu, M., Yeleswarapu, L., Chandramouli, N., Perez, L., Versace, R., Wu, A., Sambucetti, L., Lassota, P., Cohen, D., Bair, K., Wood, A. & Remiszewski, S. (2004) Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Research, 64, 689-695.
4. Barosi, G., Birgegard, G., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Kiladjian, J.J., Lengfelder, E., McMullin, M.F., Passamonti, F., Reilly, J.T., Vannucchi, A.M. & Barbui, T. (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 113, 4829-4833.
5. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. & Green, A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054-1061.
6. Bradbury, C.A., Khanim, F.L., Hayden, R., Bunce, C.M., White, D.A., Drayson, M.T., Craddock, C. & Turner, B.M. (2005) Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia, 19, 1751-1759.
7. Butler, L.M., Zhou, X., Xu, W.S., Scher, H.I., Rifkind, R.A., Marks, P.A. & Richon, V.M. (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proceedings of the National Academy of Sciences of the USA, 99, 11700-11705.
8. Campbell, P.J. & Green, A.R. (2006) The myeloproliferative disorders. The New England Journal of Medicine, 355, 2452-2466.
9. Catley, L., Weisberg, E., Tai, Y.T., Atadja, P., Remiszewski, S., Hideshima, T., Mitsiades, N., Shringarpure, R., LeBlanc, R., Chauhan, D., Munshi, N.C., Schlossman, R., Richardson, P., Griffin, J. & Anderson, K.C. (2003) NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood, 102, 2615-2622.
10. Deroanne, C.F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.M., Nusgens, B.V. & Castronovo, V. (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene, 21, 427-436.
11. Elliott, M.A. & Tefferi, A. (2005) Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. British Journal of Haematology, 128, 275-290.
12. Guerini, V., Barbui, V., Spinelli, O., Salvi, A., Dellacasa, C., Carobbio, A., Introna, M., Barbui, T., Golay, J. & Rambaldi, A. (2008) The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia, 22, 740-747.
13. Harrison, C., Kiladjian, J.J., Al-Ali, H.K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R., Knoops, L., Cervantes, F., Vannucchi, A.M., Barbui, T. & Barosi, G. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. The New England Journal of Medicine, 366, 787-798.
14. James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144-1148.
15. Kaufmann, K.B., Grunder, A., Hadlich, T., Wehrle, J., Gothwal, M., Bogeska, R., Seeger, T.S., Kayser, S., Pham, K.B., Jutzi, J.S., Ganzenmuller, L., Steinemann, D., Schlegelberger, B., Wagner, J.M., Jung, M., Will, B., Steidl, U., Aumann, K., Werner, M., Gunther, T., Schule, R., Rambaldi, A. & Pahl, H.L. (2012) A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. The Journal of Experimental Medicine, 209, 35-50.
16. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. The New England Journal of Medicine, 352, 1779-1790.
17. Larsen, T.S., Pallisgaard, N., Moller, M.B. & Hasselbalch, H.C. (2007a) The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis-impact on disease phenotype. European Journal of Haematology, 79, 508-515.
18. Larsen, T.S., Christensen, J.H., Hasselbalch, H.C. & Pallisgaard, N. (2007b) The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. British Journal of Haematology, 136, 745-751.
19. Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., Frohling, S., Dohner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J. & Gilliland, D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387-397.
20. Mann, B.S., Johnson, J.R., Cohen, M.H., Justice, R. & Pazdur, R. (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist, 12, 1247-1252.
21. Qian, D.Z., Wang, X., Kachhap, S.K., Kato, Y., Wei, Y., Zhang, L., Atadja, P. & Pili, R. (2004) The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Research, 64, 6626-6634.
22. Rambaldi, A., Dellacasa, C.M., Finazzi, G., Carobbio, A., Ferrari, M.L., Guglielmelli, P., Gattoni, E., Salmoiraghi, S., Finazzi, M.C., Di Tollo, S., D'Urzo, C., Vannucchi, A.M., Barosi, G. & Barbui, T. (2010) A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. British Journal of Haematology, 150, 446-455.
23. Rambaldi, A., Finazzi, G., Vannucchi, A.M., Martinelli, V., Rodeghiero, F., Nobile, F., Specchia, G., Pogliani, E.M., Olimpieri, O.M., Fioritoni, G., Musolino, C., Saglio, G., Sivera, P., Barosi, G., Di Tollo, S. & Barbui, T. (2011) A Phase II Study of the HDAC Inhibitor Givinostat In Combination with Hydroxyurea In Patients with Polycythemia Vera Resistant to Hydroxyurea Monotherapy. Blood (ASH Annual Meeting Abstracts), 118, 1748.
24. Rossig, L., Li, H., Fisslthaler, B., Urbich, C., Fleming, I., Forstermann, U., Zeiher, A.M. & Dimmeler, S. (2002) Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circulation Research, 91, 837-844.
25. de Ruijter, A.J., van Gennip, A.H., Caron, H.N., Kemp, S. & van Kuilenburg, A.B. (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. The Biochemical Journal, 370, 737-749.
26. Skov, V., Larsen, T.S., Thomassen, M., Riley, C.H., Jensen, M.K., Bjerrum, O.W., Kruse, T.A. & Hasselbalch, H.C. (2012) Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leukemia & Lymphoma, 53, 123-129.
27. Tefferi, A. & Vardiman, J.W. (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia, 22, 14-22.
28. Thompson, C.A. (2006) Vorinostat approved for rare lymphoma. American Journal of Health-System Pharmacy: Official Journal of the American Society of Health-System Pharmacists, 63, 2168.
29. Vannucchi, A.M. & Biamonte, F. (2011) Epigenetics and mutations in chronic myeloproliferative neoplasms. Haematologica, 96, 1398-1402.
30. Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J.V., Deininger, M., Miller, C., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, J.H. Jr, Arcasoy, M.O., Hexner, E., Lyons, R.M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Koumenis, I.L., Sun, W., Sandor, V. & Kantarjian, H.M. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. The New England Journal of Medicine, 366, 799-807.